FY2025 EPS Estimates for Palisade Bio Increased by Analyst

Palisade Bio, Inc. (NASDAQ:PALI) – Equities researchers at Brookline Capital Management increased their FY2025 earnings estimates for shares of Palisade Bio in a research note issued on Tuesday, April 8th. Brookline Capital Management analyst K. Raja now anticipates that the company will earn ($1.64) per share for the year, up from their prior forecast of ($1.86). The consensus estimate for Palisade Bio’s current full-year earnings is ($12.43) per share. Brookline Capital Management also issued estimates for Palisade Bio’s FY2026 earnings at ($0.61) EPS, FY2027 earnings at ($0.60) EPS and FY2028 earnings at ($0.57) EPS.

Palisade Bio (NASDAQ:PALI) last issued its quarterly earnings data on Monday, March 24th. The company reported ($0.69) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.39) by $1.70.

Palisade Bio Stock Performance

PALI stock opened at $0.70 on Friday. Palisade Bio has a one year low of $0.60 and a one year high of $9.65. The firm has a market cap of $3.06 million, a price-to-earnings ratio of -0.05 and a beta of 1.50. The firm has a 50-day simple moving average of $0.86 and a two-hundred day simple moving average of $1.86.

Institutional Trading of Palisade Bio

A hedge fund recently bought a new stake in Palisade Bio stock. Cetera Investment Advisers acquired a new position in shares of Palisade Bio, Inc. (NASDAQ:PALI) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 70,006 shares of the company’s stock, valued at approximately $116,000. Cetera Investment Advisers owned 2.53% of Palisade Bio at the end of the most recent quarter. Institutional investors own 11.79% of the company’s stock.

About Palisade Bio

Palisade Bio, Inc, a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage.